Edition:
United States

Navamedic ASA (NAVA.OL)

NAVA.OL on Oslo Stock Exchange

10.40NOK
26 May 2017
Change (% chg)

kr0.30 (+2.97%)
Prev Close
kr10.10
Open
kr10.10
Day's High
kr10.50
Day's Low
kr10.00
Volume
40,192
Avg. Vol
23,508
52-wk High
kr18.00
52-wk Low
kr8.00

Latest Key Developments (Source: Significant Developments)

Navamedic Q1 EBITDA at NOK 3.3 Million
Wednesday, 10 May 2017 01:01am EDT 

May 10 (Reuters) - NAVAMEDIC ASA ::Q1 EBITDA NOK 3.3 MILLION VERSUS NOK 2.1 MILLION YEAR AGO.REVENUES OF NOK 78.2 MILLION IN Q1 OF 2017 (NOK 60.8 MILLION IN Q1 2016).THE DISCONTINUATION OF THE ASPEN PARTNERSHIP END Q2 IS EXPECTED TO RESULT IN A NEGATIVE IMPACT ON THE REVENUE AND A SHORT-TERM PRESSURE ON EBITDA..  Full Article

Navamedic signs deal with Orexigen Therapeutics for Nordic launch of Mysimba
Tuesday, 2 May 2017 03:00am EDT 

May 2 (Reuters) - NAVAMEDIC ASA :NAVAMEDIC ASA: ENTERS INTO PARTNERSHIP AGREEMENT WITH OREXIGEN THERAPEUTICS FOR NORDIC LAUNCH OF MYSIMBA®.HAS ENTERED INTO A FIVE-YEAR AGREEMENT WITH OREXIGEN THERAPEUTICS IRELAND, LTD., FOR NORDIC MARKETING AND DISTRIBUTION OF MYSIMBA®, A PRESCRIPTION PHARMACEUTICAL..NAVAMEDIC EXPECTS TO BEGIN MARKETING PRODUCT DURING Q4 2017 FOR AN INITIAL PERIOD OF FIVE YEARS, RENEWABLE FOR AN ADDITIONAL FIVE-YEAR PERIOD, ACCORDING TO TERMS OF AGREEMENT.  Full Article

Navamedic enters into distribution agreement for Sippi in Italy
Friday, 7 Apr 2017 02:00am EDT 

NAVAMEDIC ASA : NAVAMEDIC ASA: ENTERS INTO DISTRIBUTION AGREEMENT FOR SIPPI® IN ITALY .HAS ENTERED AN AGREEMENT WITH ITALY- BASED SIM ITALIA SRL (SIM ITALIA), A LEADING DISTRIBUTOR OF STERILE MEDICAL DEVICES, FOR LAUNCH OF SIPPI® IN ITALY.  Full Article

Navamedic: Sippcoat granted European patent
Friday, 20 Jan 2017 02:22am EST 

Navamedic Asa : European Patent Office has granted a patent for Sippcoat to be used in any urine handling system to help prevent bacteria migration .Says this yields major licensing opportunities and hence an additional multi-million NOK market potential for Navamedic.  Full Article

Navamedic appoints Toril Marie Ås new CFO
Tuesday, 23 Aug 2016 04:18am EDT 

Navamedic ASA : Appoints new CFO .Toril Marie Ås has been Navamedic's interim CFO since February 1, 2016.  Full Article

Navamedic Q2 EBITDA swings to loss of NOK 1.6 million
Thursday, 18 Aug 2016 01:01am EDT 

Navamedic ASA : Q2 revenue 66.7 million Norwegian crowns ($8.15 million)versus 59.6 million crowns year ago . Q2 EBITDA loss 1.6 million crowns versus profit 3.5 million crowns year ago .Distribution of angina prevention medicine, Imdur, expected to contribute annual future revenue of 70 million-100 million crowns; initial revenue expected during H2 2016.  Full Article

Navamedic ends partnership with Aspen Pharma in 2017
Tuesday, 5 Jul 2016 03:51am EDT 

Navamedic ASA : Ends partnership with Aspen Pharma in 2017 . Partnership termination is in line with Navamedic's June 13, 2016 announcement on strategic partnership with TopRidge Pharma Limited .Current contract expires mid-May 2017.  Full Article

Navamedic: New patent for Sippi line extension
Wednesday, 15 Jun 2016 02:09am EDT 

Navamedic ASA : Announces new patent for Sippi line extension .Swedish Patent and Registration Office has granted new patent pertaining to Sippcoat.  Full Article

Navamedic: 8-year distribution agreement with TopRidge Pharma
Monday, 13 Jun 2016 08:18am EDT 

Navamedic ASA : Enters into strategic partnership and 8-year distribution agreement with TopRidge Pharma Limited . Agreement represents expected annual revenues of 70 million - 100 million Norwegian crowns ($8.45 million - $12.07 million) . Expects to see an effect on revenues during Q2 2016 . TopRidge Pharma (Ireland), wholly owned unit of TopRidge Pharma, will buy 1.4 million new shares in Navamedic, and become major shareholder in company . Will issue 1,417,522 new shares to TopRidge Pharma (Ireland) at 8.00 crowns per share .Says "we have entered a letter of intent with TopRidge Pharma for a collaboration to launch Sippi in China".  Full Article

Navamedic Q1 EBITDA falls to NOK 2.1 million
Wednesday, 11 May 2016 01:01am EDT 

Navamedic ASA : Q1 sales 60.8 million Norwegian crowns versus 61.8 million crowns year ago . Q1 EBITDA 2.1 million crowns versus 4.1 million crowns year ago .Navamedic Medtech business area is expected to have negative impact on overall profitability in 2016, but is expected to turn into cash flow positive status during 2017.  Full Article

More From Around the Web

BRIEF-Navamedic Q1 EBITDA at NOK 3.3 Million

* REVENUES OF NOK 78.2 MILLION IN Q1 OF 2017 (NOK 60.8 MILLION IN Q1 2016)